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Abstract
Background: Elevated plasma free fatty acid (FFA) levels have been linked to the development of atherosclerosis.
However, how FFA causes atherosclerosis has not been determined. Because fatty acid translocase (FAT/CD36) is
responsible for the uptake of FFA, we hypothesized that the atherogenic effects of FFA may be mediated via CD36.
Results: We tested this hypothesis using cultured rat aortic smooth muscle cells (SMCs) treated with oleic acid (OA).
We found that OA induces lipid accumulation in SMCs in a dose dependent manner. Rat aortic SMCs treated for 48
hours with OA (250 μmol/L) became foam cells based on morphological (Oil Red O staining) and biochemical (5 times
increase in cellular triglyceride) criteria. Moreover, specific inhibition of CD36 by sulfo-N-succinimidyl oleate significantly
attenuated OA induced lipid accumulation and foam cell formation. To confirm these results in vivo, we used ApoE-
deficient mice fed with normal chow (NC), OA diet, NC plus lipolysis inhibitor acipimox or OA plus acipimox. OA-fed
mice showed increased plasma FFA levels and enhanced atherosclerotic lesions in the aortic sinus compared to the NC
group (both p < 0.01). This effect was partially reversed by acipimox (lesion area: OA: 3.09 ± 0.10 ×105 μm2 vs. OA plus
acipimox: 2.60 ± 0.10 ×105 μm2, p < 0.05; FFA: OA: 0.91 ± 0.03 mmol/L vs. OA plus acipimox: 0.78 ± 0.03 mmol/L,
p <0.05).
Conclusions: These findings suggest that OA induces smooth muscle foam cell formation and enhances
atherosclerotic lesions in part though CD36. Furthermore, these findings provide a novel model for the
investigation of atherosclerosis.
Background
Foam cell formation is an important process in the devel-
opment of atherosclerosis [1]. Foam cells have been
demonstrated to be of either macrophage or smooth mus-
cle cell (SMC) origin [2]. Circulating cholesterol has been
traditionally recognized as an important risk factor of
atherosclerosis. Macrophages can easily be induced to
transform into foam cells by loading modified low density
lipoprotein (LDL) cholesterol donors, including ox-LDL.
However, the method that induces SMC to form foam cell
through cholesterol loading has been challenged [3].
Attempts to extensively load vascular SMC with choles-
terol have been largely unsuccessful [4-6]. This phenom-
enon suggests that there is another mechanism underlying
the formation of SMC-derived foam cells. To date, the
mechanism by which vascular SMC could accumulate
large stores of lipids remains elusive.
Cholesterol and triglyceride are the major components
of atherosclerotic plaques. Cholesterol esters and trigly-
cerides all contain fatty acids. Pilz et al [7] have reported
that free fatty acids (FFA) are independently associated
with cardiovascular mortality in subjects with coronary
artery disease, indicating that FFA might promote the
development of atherosclerosis. Although FFA is linked
to the pathogenesis of atherosclerosis [8], the mechanism
by which FFA regulates the development of atherosclero-
sis is still unknown [9].
Several studies have demonstrated that FFA might
cause a significant amount of lipid accumulated in both
hepatic [10] and skeletal muscle cells [11]. Fatty acid
translocase (FAT/CD36), originally identified as glyco-
protein IV on platelets, is an 88-kDa integral membrane
* Correspondence: yongjiany@yahoo.cn
† Contributed equally
Department of Cardiology, General Hospital of PLA Chengdu Military Area
Command, Chengdu 610083, PR China
Ma et al. Lipids in Health and Disease 2011, 10:53
http://www.lipidworld.com/content/10/1/53
© 2011 Ma et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
protein that has multiple legends and is widely expressed
in different cell types [12], including vascular SMCs [13].
Recent studies have shown that CD36 is also a crucial
transporter for FFA [14]. Previous observations have sug-
gested that CD36 deficiency may provide a more athero-
genic environment to accelerate the development of
atherosclerosis [13], causing a significant increase in fast-
ing levels of FFA.
Therefore, we hypothesized that FFA might induce
smooth muscle foam cell formation and enhance athero-
sclerotic lesion development via CD36. In the present
study, we present a model of smooth muscle foam cell
formation. We propose that elevated levels of FFA could
increase the uptake of fatty acids in vascular SMC via
CD36 and subsequently induce the formation of smooth
muscle foam cells and accelerate the development of
atherosclerotic lesions in ApoE-deficient (ApoE-/-) mice.
Results
Induction of vascular smooth muscle foam cell formation
by oleic acid
We examined lipid accumulation by using Oil Red O
staining (Figure 1A). After incubation with oleic acid
(OA) for 48 hours, rat SMC assumed the morphological
appearance of foam cells with significant lipid accumula-
tion; in contrast, no lipid droplets were found in the
untreated cells. The visual abundance of lipid droplets
was grossly correlated with OA concentration in the
treatment. Measurement of triglyceride and cholesterol
esters confirmed cellular accumulation of lipids. Incuba-
tion with OA increased intracellular triglyceride levels in
a dose-dependent manner (p < 0.01, Figure 1B). How-
ever, intracellular cholesterol esters were slightly, but
not significantly, increased by incubation with OA at a
concentration of 100 μmol/L and were not further
increased by OA at higher concentrations (Figure 1C).
OA-induced vascular smooth muscle foam cell formation
is CD36-dependent
When rat SMCs were incubated with OA (250 μmol/L)
plus CD36 inhibitor sulfo-N-succinimidyl oleate (SSO),
cellular lipid inclusions were significantly decreased
compared with cells treated only with OA (Figure 2A).
Biochemical measurements were consistent with the Oil
Red O staining results; compared with the OA-treated
SMCs, intracellular triglyceride levels were significantly
reduced in cells treated with OA plus SSD (p < 0.01,
Figure 2B). However, SSD did not affect intracellular
cholesterol ester levels in cells treated with OA (Figure
2C). Additionally, intracellular triglyceride and choles-
terol ester content remained constant in the SMCs trea-
ted with SSO only (data not shown). These results
suggested that OA-induced vascular smooth muscle
foam cell formation is CD36-dependent. Furthermore,
the protein level of CD36 in vascular SMCs was not
affected by either OA or SSO (Figure 2D). Similarly,
neither OA nor SSO influenced the mRNA level of
CD36 in vascular SMCs (Figure 2E).
OA modulates vascular SMC phenotype
We determined the protein and mRNA levels of smooth
muscle a-actin (SMaA, a marker of undifferentiated
proliferating vascular SMCs) and embryonic smooth
muscle myosin heavy chain (SMemb, a marker of undif-
ferentiated proliferating vascular SMCs) in cultured vas-
cular SMCs using immunofluorescence analysis. The
protein expression of SMaA was downregulated while
SMemb was upregulated in vascular SMCs treated with
OA at a concentration of 250 μmol/L (both p < 0.01,
Figure 3A and 3B). However, treatment with SSO signif-
icantly attenuated OA-induced changes in the expres-
sion of SMaA and SMemb (both p < 0.05, Figure 3A
and 3B).
OA enhances atherosclerotic lesion development
Oil Red O stained sections of the aortic root from
ApoE-/- mice fed with normal chow (NC) or OA showed
that OA-fed mice had increased lesion area compared to
NC-fed mice (2.23 ± 0.06 ×105 μm2 vs. 3.09 ± 0.10 ×105
μm2, p < 0.01, Figure 4A and 4B). This effect was par-
tially reversed by acipimox (OA: 3.09 ± 0.10 ×105 μm2
vs. OA+A: 2.60 ± 0.10 ×105 μm2, p < 0.05, Figure 4A
and 4B). In addition, oral administration of acipimox
did not influence the atherosclerotic lesion of ApoE-/-
mice fed with NC (NC: 2.23 ± 0.06 ×105 μm2 vs. NC+A:
2.16 ± 0.03 ×105 μm2, p > 0.05, Figure 4A and 4B). In
OA-treated ApoE-/- mice, the plasma FFA levels in the
fasting state were elevated compared with mice fed with
a NC diet (0.70 ± 0.04 mmol/L vs. 0.91 ± 0.03 mmol/L,
p < 0.01, Figure 4C). OA-induced increases in plasma
FFA levels were partially reversed by acipimox (OA:
0.91 ± 0.03 mmol/L vs. OA+A: 0.78 ± 0.03 mmol/L, p <
0.05, Figure 4C). Additionally, in ApoE-/- mice fed with
a NC diet, the level of plasma FFA was also decreased
by treatment with acipimox (NC: 0.70 ± 0.04 mmol/L
vs. NC+A: 0.60 ± 0.03 mmol/L, p < 0.05, Figure 4C).
Discussion
There are two novel findings in the present study. First,
OA induces smooth muscle foam cell formation in a
dose dependent manner and enhances atherosclerotic
lesion development in ApoE-/- mice. Second, the athero-
genic effects of OA are CD36 dependent. These findings
suggest that FFA directly causes the formation of vascu-
lar SMC derived foam cells and accelerates atherosclero-
sis through CD36.
There have been a number of recent studies that have
demonstrated the existence of SMC derived foam cells
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Figure 1 Vascular smooth muscle foam cell formation is induced by OA treatment. (A) Cellular lipid accumulation in rat aortic SMCs after
incubation for 48 hours with indicated concentrations of OA. Magnification ×400. Triglyceride (B) and cholesterol ester (C) levels normalized to
cellular protein content in rat aortic SMCs. Data are expressed as mean ± SEM. ** p < 0.01 compared with the control group, ## p < 0.01
compared with the cells treated with 100 μmol/L of OA. OA, oleic acid; SMCs, smooth muscle cells.
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Figure 2 OA-induced foam cell formation is CD36-dependent. (A) Cellular lipid accumulation in rat aortic SMCs after incubation for 48 hours
with vehicle (control), OA (250 μmol/L), or OA (250 μmol/L) plus SSO (250 μmol/L). Magnification ×400. Triglyceride (B) and cholesterol ester (C)
levels normalized to cellular protein content in rat aortic SMCs. (D) CD36 was determined by western blotting using a specific antibody. Equal
protein loading was confirmed using b-actin antibody. The graph below the blot shows quantification. (E) CD36 was determined by RT-PCR.
Equal RNA loading was confirmed using b-actin primers. The graph below the blot shows quantification. Data are expressed as mean ± SEM. **
p < 0.01 compared with the control group, ## p < 0.01 compared with the cells treated with OA alone. OA, oleic acid; SMCs, smooth muscle
cells; SSO, sulfosuccinimidyl oleate.
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in atherosclerotic lesions [15]. However, the understand-
ing of underlying mechanisms has been very limited
[16]. There have been numerous efforts to establish
in vitro approaches to induce smooth muscle foam cell
formation, but with only limited success [3-5]. Vascular
SMCs accumulate only small amounts of cholesteryl
esters when exposed to modified LDL [4]. This failure
to overaccumulate cholesteryl esters is due to an
LDL-mediated downregulation of cell surface LDL
receptors [17]. These results demonstrated that SMCs
A
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Figure 3 OA modulates vascular SMC phenotype. (A) Immunofluorescence staining of SMaA and SMemb proteins in rat aortic SMCs after
incubation for 48 hours with vehicle (control), OA (250 μmol/L), or OA (250 μmol/L) plus SSO (250 μmol/L). Magnification ×400. (B, C)
Summarized data showing the average fluorescence intensity in cells from each group. Data are expressed as mean ± SEM. ** p < 0.01
compared with the control group, # p < 0.05 compared with the cells treated with OA alone. OA, oleic acid; SMCs, smooth muscle cells; SSO,
sulfosuccinimidyl oleate; SMaA, smooth muscle a-actin; SMemb, embryonic smooth muscle myosin heavy chain.
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Figure 4 OA enhances atherosclerotic lesion development. (A) Oil Red O staining of atherosclerotic lesions in the aortic root at the level of
the aortic valves. Magnification ×40. (B) Quantitative analyses of the proximal aorta atherosclerotic lesion areas in the normal chow (NC), NC plus
acipimox (NC+A), oleic acid (OA) and OA plus acipimox (OA+A) groups. (C) Plasma levels of FFA in the four groups. Data are expressed as mean
± SEM. n = 6 mice per group. * p < 0.05, ** p < 0.01 compared with the control group, # p < 0.05 compared with the cells treated with OA
alone. NC, normal chow; OA, oleic acid; A, acipimox; FFA, free fatty acid.
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are insensitive to LDL. Using a saturated fatty acid, OA,
we successfully reproduced, in vitro, the major biochem-
ical and morphological alterations that occur within
SMCs in vivo during atherosclerosis. The current study
developed an effective and convenient way to induce the
formation of smooth muscle foam cells.
It has been accepted that nonesterified FFA contributes
to cardiovascular mortality and is an independent risk fac-
tor of atherosclerosis [9]. However, the mechanisms by
which FFA causes the development of atherosclerotic
lesion are unknown. Previous studies have demonstrated
that FFA activates the immune system and promotes a
proinflammatory state, which may contribute to its
proatherogenic action [18]. The present study provides a
direct mechanism by which FFA can deliver significant
lipid accumulation to SMCs and induce foam cell forma-
tion. The CD36 is one of a number of fatty acid transpor-
ters that mediate the uptake of FFA by adipocytes and
muscle cells. The current findings provide direct evidence
that CD36 is a key determinant of the atherogenic actions
of OA. CD36 is not only present on vascular SMCs but
also on the surface of monocytes/macrophages. Addition-
ally, CD36 is also involved in uptake of proatherogenic
modified forms of LDL. A previous study demonstrated
that the absence of CD36 on macrophages may protect
against atherosclerosis in ApoE-/- mice [19], strongly sup-
porting a pro-atherogenic role for CD36. These results
provide new insights into the pro-atherogenic mechanisms
of CD36 by mediating the uptake of FFA other than modi-
fied LDL uptake. CD36 might become a novel target for
the prevention and treatment of atherosclerosis.
We also demonstrated that elevated plasma levels of
FFA in ApoE-/- mice can accelerate atherosclerosis, which
confirmed the atherogenic action of FFA in vivo. We
addressed whether reducing FFA levels ameliorates ather-
osclerosis. Most FFA in plasma is derived from hydrolysis
of adipose tissue triglyceride stores. Acipimox, as an antili-
polytic agent, is an effective agent for lowering plasma
FFA [20]. We found that acipimox significantly reduced
plasma FFA levels and attenuated OA-induced enhance-
ment of atherosclerotic lesions in ApoE-/- mice on an OA
diet. In addition, acipimox remarkably decreased plasma
FFA levels in ApoE-/- mice on a NC diet, but did not influ-
ence the development of atherosclerotic lesions. This find-
ing suggests that acipimox may ameliorate atherosclerosis
by lowing plasma levels of FFA that have been elevated.
Therefore, acipimox might become a potent agent for the
treatment of atherosclerosis associated with elevated
plasma FFA levels.
Conclusions
In conclusion, the present results demonstrate that OA
induces smooth muscle foam cell formation and
enhances atherosclerotic lesion development via CD36.
Moreover, the OA-induced acceleration of atherosclero-
sis can be reversed by reducing plasma FFA levels using
the antilipolytic agent acipimox. The current study also
provides a model of smooth muscle foam cells for the
study of atherosclerosis. The present findings may con-




Male Wistar rats, 6 to 8 weeks of age, were obtained
from a local animal center. ApoE-/- mice were pur-
chased from the Model Animal Research Center of
Nanjing University. Animals were housed under a 12 h/
12 h day/night cycle with ad libitum food and water.
Experimental procedures were approved by the Hospital
Animal Care and Use Committee.
Aortic SMC culture
Aortic SMCs were obtained from the thoracic aorta of
Wistar rats and cultured using previously described tis-
sue explant methods [21]. SMCs were grown in high-
glucose Dulbecco’s modified Eagle’s medium (DMEM;
Hyclone, Logan, UT, USA) supplemented with 10% fetal
calf serum (FBS; Hyclone, Logan, UT, USA). Cultures
were maintained at 37°C in a humidified atmosphere of
95% air/5% CO2. The smooth muscle phenotype of cul-
tured cells was verified by positive immunofluorescence
for smooth muscle specific a-actin.
SSO synthesis
SSO was synthesized according to the method reported
earlier by Isenberg et al [22]. 0.25 mmol of OA,
0.25 mmol of N-hydroxysulfosuccinimide and 0.275 mmol
of dicyclohexylcarbodiimide were reacted in 0.5 mL anhy-
drous N, N-dimethylformamide overnight at room tem-
perature. After crystallizing out the dicyclohexylurea, the
solution was filtered and chilled. Then, the product was
precipitated out of solution by the addition of cold ethyl
acetate and dried under vacuum.
Induction of smooth muscle foam cell formation
Cultured vascular SMCs were plated on cover slides in
six-well plates and maintained in culture media until
the cells reached 95% confluence. Experiment 1: The
cells were incubated for 48 hours with 0, 100, 250 and
500 μmol/L of OA in DMEM culture medium. After
that, the cells were washed with phosphate-buffered sal-
ine, fixed with 4% paraformaldehyde, and stained with
Oil Red O, which detects neutral lipids such as choles-
teryl esters and triglycerides. Intracellular triglyceride
and cholesteryl esters were detected. Experiment 2: The
cells were divided into three groups: control (treated
with vehicle), OA (treated with 250 μmol/L of OA), and
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OA+SSO (treated with 250 μmol/L of OA plus
250 μmol/L of SSO). After incubation for 48 hours, Oil
Red O staining of the cells was performed, and the
intracellular triglyceride and cholesteryl esters were
measured. The cells were collected for the detection of
CD36 expression.
Western blot analysis
Cell lysate was prepared by lysing the cells with buffer
containing 1% Triton X-100, 150 mM NaCl, 1 mM EDTA,
2.5 mM sodium pyrophosphate, 1 mM b-glyceropho-
sphate, 1 mM Na3VO4, 1 μg/mL leupeptin, 1 μg/mL
aprotinin, and 20 mM Tris (pH 7.5) [23]. The lysates were
centrifuged to remove cell debris. Protein concentration
was determined by Bio-Rad protein assay reagent (Bio-Rad
Laboratories, USA). Lysate was electrophoretically trans-
ferred onto a nitrocellulose membrane and immunoblotted
with rabbit anti-rat CD36 IgG (1:500 dilution, monoclonal,
Sigma-Aldrich Co., USA). The blots were incubated with a
horseradish peroxidase-conjugated secondary antibody
(1:1000 dilution, Santa Cruz Biotechnology, USA), and the
bound antibody was visualized using a colored reaction.
The relative band intensity was quantified by the use of
Quantity One software (Bio-Rad). Equal loading of protein
was confirmed by measuring b-actin expression.
Semi-quantitative reverse-transcription-PCR (RT-PCR)
Total RNA was extracted from cells with Tripure reagent
(Roche Diagnostics Corp., Indianapolis, IN, USA) accord-
ing to manufacturer instructions [24]. Semiquantitative
RT-PCR for CD36 was performed as described pre-
viously. The primers for rat CD36 mRNA were as
follows: 5’-GTG CAA AGA AGG AAA GCC-3’ (sense)
and 5’-CAT CAC TAC TCC AAC ACC-3’ (antisense).
The primers for rat b-actin mRNA were as follows: 5’-
GAA GAT CCT GAC CGA GCG TG-3’ (sense) and 5’-
CGT ACT CCT GCT TGC TGA TCC-3’ (antisense).
Equal loading of RNA was confirmed by measuring
b-actin expression. The PCR products were visualized by
electrophoresis in 1% agarose gel (Bio-Rad, CA, USA)
with ethidium bromide (0.5 μg/ml; Sigma, MO, USA).
Immunofluorescence
Cultured vascular SMCs were rinsed with PBS, fixed
with ice-cold acetone for 15 minutes, incubated in
blocking solution (10% FBS) for 20 minutes at room
temperature, and incubated with rabbit anti-SMaA or
rabbit anti-SMemb (1:200 dilution, Santa Cruz Biotech-
nology, USA) overnight at 4°C. The cells were washed
and incubated with antibody conjugated to a fluorescent
probe (rhodamine-conjugated goat anti-rabbit IgG or
FITC-conjugated goat anti-rabbit IgG) (1:100 dilution,
Santa Cruz Biotechnology, USA) for 30 min at room
temperature. After removing the unbound secondary
antibodies by washing the preparations with PBS, ima-
ging was performed using a fluorescence microscope
(Nikon TE2000, USA).
Animal treatment
Male ApoE-/- mice, 6 to 8 weeks of age, were rando-
mized to the NC, OA, or OA plus lipolysis inhibitor aci-
pimox (OA+A) groups. OA diet contains 10% oil. Mice
in OA+A group were fed OA diet and treated by oral
gavage with 20 mg/kg/day of acipimox. The administra-
tion period lasted 4 weeks.
Assessment of atherosclerosis
The heart with aorta was fixed overnight in paraformal-
dehyde and then embedded in optimal cutting tempera-
ture cryosectioning medium. Atherosclerotic fatty streak
lesions in the aortic root were analyzed using Oil Red O
staining and were counterstained with hematoxylin [25].
Atherosclerotic lesions were captured as digital images
by a color camera attached to a microscope (Nikon
TE2000, USA), and total mean lesion area was quanti-
fied using image analysis software.
Plasma FFA level measurement
Fasting blood samples were obtained and plasma FFA
was determined by a microplate enzymatic assay using a
commercially available kit (Jiancheng Bioengineering
Institute, Nanjing, China). The measurements were per-
formed according to manufacturer guidelines.
Statistical analysis
Continuous data are presented as mean ± SEM. Com-
parisons between groups were determined by one-way
ANOVA with a post hoc Student’s t-test (SPSS Inc.,
Chicago, IL). Probabilities of p < 0.05 were considered
statistically significant.
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